MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$5,139K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from issuance of common...
Other current assets
Stock-based compensation expense
Others
Negative Cash Flow Breakdown
Purchases of short-term investme...
Net income (loss)
Accounts receivable
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net income (loss)
-4,834
-4,145
-3,406
-4,303
Stock-based compensation expense
394
749
1,517
1,225
Depreciation and amortization expense
14
29
49
36
Accretion of liability related to sale of future revenues
173
814
878
891
Amortization (accretion) of investment premiums (discounts)
29
0
-84
83
Non-cash operating lease expense
191
185
263
320
Loss on impairment of lease right-of-use asset
0
0
0
0
Gain on derecognition of lease liabilities
0
-
2,651
0
Other non-cash items, net
51
49
-457
4
Accounts receivable
318
-1,253
-660
1,913
Inventories
0
0
0
0
Other current assets
-474
1,336
-326
367
Other assets
-125
15
27
-46
Accounts payable
187
510
-191
-983
Accrued compensation
70
-642
-796
-485
Accrued research and development expenses
16
-41
-260
-629
Other current liabilities
247
-166
-839
-2,239
Deferred revenue
91
-32
-295
-596
Operating lease liabilities
-211
-285
-552
-711
Other long-term liabilities
21
0
0
0
Net cash used in operating activities
-3,338
-3,073
-5,697
-9,787
Purchases of short-term investments
6,626
-
0
2,466
Proceeds from maturities and sales of short-term investments
0
0
7,885
1
Purchases of property and equipment
-
-
0
0
Proceeds from sale of property and equipment
0
-
555
44
Net cash (used in) provided by investing activities
-6,626
0
8,440
-2,421
Proceeds from issuance of common stock through atm facilities, net
4,825
2,951
-25
1,496
Proceeds from sale of pre-funded warrants to purchase common stock in an underwritten registered direct offering or registered direct offering, net
0
-
0
-461
Proceeds from employee stock awards
0
-
22
12
Principal payments on finance lease obligations
0
0
0
0
Other financing activities, net
0
-
0
0
Net cash provided by financing activities
4,825
2,951
-3
1,047
Increase (decrease) in cash, cash equivalents and restricted cash
-5,139
-122
2,740
-11,161
Cash, cash equivalents and restricted cash at beginning of period
8,360
8,482
5,742
25,176
Cash, cash equivalents and restricted cash at end of period
3,221
8,360
8,482
5,742
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from issuance of
common stock through...
$4,825K
Net cash provided by
financing activities
$4,825K
(-67.95%↓ Y/Y)
Increase (decrease) in
cash, cash...
-$5,139K
(37.88%↑ Y/Y)
Canceled cashflow
$4,825K
Other current assets
-$474K
(92.37%↑ Y/Y)
Stock-based compensation
expense
$394K
(-94.38%↓ Y/Y)
Other current
liabilities
$247K
(117.18%↑ Y/Y)
Non-cash operating lease
expense
$191K
(-95.67%↓ Y/Y)
Accounts payable
$187K
(106.10%↑ Y/Y)
Accretion of liability
related to sale of future...
$173K
(-90.44%↓ Y/Y)
Other assets
-$125K
(-3225.00%↓ Y/Y)
Deferred revenue
$91K
(100.10%↑ Y/Y)
Accrued compensation
$70K
(101.73%↑ Y/Y)
Other non-cash items,
net
$51K
(-90.68%↓ Y/Y)
Other long-term
liabilities
$21K
(2000.00%↑ Y/Y)
Accrued research and
development expenses
$16K
(100.23%↑ Y/Y)
Depreciation and
amortization expense
$14K
(-99.31%↓ Y/Y)
Net cash (used in)
provided by investing...
-$6,626K
(-154.63%↓ Y/Y)
Net cash used in
operating activities
-$3,338K
(90.59%↑ Y/Y)
Canceled cashflow
$2,054K
Purchases of short-term
investments
$6,626K
(22.27%↑ Y/Y)
Net income (loss)
-$4,834K
(-111.97%↓ Y/Y)
Accounts receivable
$318K
(121.46%↑ Y/Y)
Operating lease
liabilities
-$211K
(94.96%↑ Y/Y)
Amortization (accretion) of
investment premiums...
$29K
(111.24%↑ Y/Y)
Buy us a coffee
Atara Biotherapeutics, Inc. (ATRA)
Atara Biotherapeutics, Inc. (ATRA)